Brown Advisory’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Brown Advisory’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-6,650	Closed	-$241K	–	1079
2019 Q4	$241K	Buy	+6,650	New	+$204K	﹤0.01%	935
2019 Q2	–	Sell	-39,512	Closed	-$1.04M	–	1346
2019 Q1	$1.04M	Buy	39,512 +290	+0.7%	+$6.87K	﹤0.01%	797
2018 Q4	$766K	Buy	39,222 +314	+0.8%	+$6.16K	﹤0.01%	814
2018 Q3	$762K	Sell	38,908 -2	-0%	-$38	﹤0.01%	875
2018 Q2	$644K	Buy	38,910 +4,767	+14%	+$72.7K	﹤0.01%	910
2018 Q1	$485K	Buy	34,143 +5,842	+21%	+$86.3K	﹤0.01%	845
2017 Q4	$413K	Buy	28,301 +16,817	+146%	+$236K	﹤0.01%	942
2017 Q3	$145K	Buy	+11,484	New	+$146K	﹤0.01%	1141
2017 Q2	–	Sell	-18,856	Closed	-$279K	–	1257
2017 Q1	$279K	Buy	+18,856	New	+$305K	﹤0.01%	1006
2016 Q4	–	Sell	-10,841	Closed	-$196K	–	1172
2016 Q3	$196K	Buy	+10,841	New	+$212K	﹤0.01%	1016

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Brown Advisory's HZNP Position: Q1 2020 in Review

Brown Advisory sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2020, closing a stake of 6,650 shares — an estimated $241K sold.

Brown Advisory first reported a position in HZNP in Q3 2016 and held it in 10 quarters. The position peaked at $1.04M in Q1 2019. 295 funds tracked by Wall St. Rank hold HZNP as of Q1 2020.

Brown Advisory reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2020 after selling out during the quarter.
Brown Advisory sold 6,650 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2020, an estimated $241K.
Brown Advisory first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2016 and held it in 10 quarters.
Brown Advisory's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.04M in Q1 2019.
295 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2020.

Based on Brown Advisory's 13F filing for Q1 2020, filed 15 May 2020.